Potential applications of catestatin in cardiovascular diseases

Yilin Zhao1, Dan Zhu2

  • 1The Departments of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Insights

Catestatin (CST) is a newly discovered factor involved in cardiovascular diseases. This review explores its protective role and mechanisms in heart conditions.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Catestatin (CST) was identified in 1997 for its catecholamine-inhibitory activity.
  • CST acts as a potent inhibitor of catecholamine secretion and regulates histamine release.
  • Emerging evidence suggests CST's involvement in cardiovascular diseases, but its precise role remains unclear.

Purpose of the Study:

  • To review current research on Catestatin (CST) and its association with cardiovascular diseases.
  • To summarize findings from basic research and clinical trials concerning CST.
  • To elucidate the potential protective mechanisms of CST in cardiovascular conditions.

Main Methods:

  • Literature review of studies on CST and cardiovascular diseases.
  • Inclusion of data from MedLine via PubMed searches.
  • Incorporation of findings from the authors' own investigations.

Main Results:

  • Accumulating evidence indicates CST's involvement in cardiovascular diseases.
  • The exact protective role and mediating mechanisms of CST require further investigation.
  • This review synthesizes existing knowledge on CST's cardiovascular implications.

Conclusions:

  • CST is implicated in cardiovascular diseases, potentially offering a protective effect.
  • Further research is needed to fully understand CST's mechanisms of action in cardiovascular health.
  • Comprehensive review of existing data highlights the significance of CST in cardiology.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K